The EBMT will be actively participating in the 66th ASH Annual Meeting & Exposition that will take place December 7-10, 2024, in San Diego, California, and online.
The EBMT will present 48 communications in the different oral or poster sessions. You will find below the list of these abstracts including title, time and location of presentations. You can click on the title to view the full abstract from the ASH website.
Congratulations to all co-authors and thank you all for your continuous support!
ORAL
“Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
Result Type: Paper
Number: 112
Presenter: Giorgio Ottaviano
Program: Oral and Poster Abstracts
Session: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: 'In with the Old, In with the New': Outcomes of Conventional and Novel Therapeutic Paradigms in Aggressive Lymphoid Malignancies
Time and Location:
Saturday, December 7, 2024: 9:30 AM-11:00 AM
Room 6B (San Diego Convention Center)
Dynamics of Oligoclonal Hematopoiesis in Severe Aplastic Anemia Patients Undergoing Immunosuppressive Treatment: Longitudinal Somatic Mutation Analysis from the EBMT Race Trial
Result Type: Paper
Number: 33
Presenter: Austin Kulasekararaj
Program: Oral and Poster Abstracts
Session: 508. Bone Marrow Failure: Acquired: Biological Findings Associated with the Pathophysiology and Outcomes of Aplastic Anemia and PNH
Time and Location:
Saturday, December 7, 2024: 9:30 AM-11:00 AM
Room 11 (San Diego Convention Center)
Allogeneic Transplantation for Sickle Cell Disease Offers High Rates of Cure with Low Incidence of Severe Chronic GVHD in Both Children and Adults: Real World Data from 2010-2021. An Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
Result Type: Paper
Number: 176
Presenter: Josu de la Fuente
Program: Oral and Poster Abstracts
Session: 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Therapeutic Advances in Sickle Cell Disease
Time and Location:
Saturday, December 7, 2024: 2:00 PM-3:30 PM
Hall B (San Diego Convention Center)
Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
Result Type: Paper
Number: 399
Presenter: Imke Karsten
Program: Oral and Poster Abstracts
Session: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Learning from the Real World: Predictors of Outcomes in Understudied Lymphomas and Underrepresented Populations
Time and Location:
Saturday, December 7, 2024: 4:00 PM-5:30 PM
Room 6A (San Diego Convention Center)
Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
Result Type: Paper
Number: 305
Presenter: Camilla Frieri
Program: Oral and Poster Abstracts
Session: 508. Bone Marrow Failure: Acquired: Emerging Data in the Treatment of Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Time and Location:
Saturday, December 7, 2024: 4:00 PM-5:30 PM
Room 11 (San Diego Convention Center)
Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study
Result Type: Paper
Number: 302
Presenter: Antonio Risitano
Program: Oral and Poster Abstracts
Session: 508. Bone Marrow Failure: Acquired: Emerging Data in the Treatment of Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Time and Location:
Saturday, December 7, 2024: 4:00 PM-5:30 PM
Room 11 (San Diego Convention Center)
Younger Haploidentical Versus Older Matched Sibling Donors in Acute Lymphoblastic Leukemia: A Study from the ALWP of EBMT
Result Type: Paper
Number: 508
Presenter: Eolia Brissot
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Conditioning and Donor Selection in Allogeneic Stem Cell Transplantation
Time and Location:
Sunday, December 8, 2024: 9:30 AM-11:00 AM
Room 6B (San Diego Convention Center)
Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation from Unrelated and Matched Sibling Donors in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT
Result Type: Paper
Number: 505
Presenter: Arnon Nagler
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Conditioning and Donor Selection in Allogeneic Stem Cell Transplantation
Time and Location:
Sunday, December 8, 2024: 9:30 AM-11:00 AM
Room 6B (San Diego Convention Center)
Autologous and Allogeneic Stem Cell Transplantation for Major T-Cell Lymphoma Entities: An Analysis of the EBMT Lymphoma Working Party
Result Type: Paper
Number: 464
Presenter: Evgenii Shumilov
Program: Oral and Poster Abstracts
Session: 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: When Old Meets New in T Cell Lymphomas
Time and Location:
Sunday, December 8, 2024: 9:30 AM-11:00 AM
Ballroom 20CD (San Diego Convention Center)
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia – a Study on Behalf of the Chronic Malignancies Working Party of the EBMT
Result Type: Paper
Number: 600
Presenter: Olivier Tournilhac
Program: Oral and Poster Abstracts
Session: 723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Long-term Outcomes Including in Bone Marrow Failure and Rare Diseases
Time and Location:
Sunday, December 8, 2024: 12:00 PM-1:30 PM
Room 11 (San Diego Convention Center)
Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT
Result Type: Paper
Number: 607
Presenter: Christian Chabannon
Program: Oral and Poster Abstracts
Session: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Driving the CARs Home: Real-World Safety and Outcomes of CAR-T Cell Therapies
Time and Location:
Sunday, December 8, 2024: 12:00 PM-1:30 PM
Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)
Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
Result Type: Paper
Number: 595
Presenter: Antonio Risitano
Program: Oral and Poster Abstracts
Session: 723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Long-term Outcomes Including in Bone Marrow Failure and Rare Diseases
Time and Location:
Sunday, December 8, 2024: 12:00 PM-1:30 PM
Room 11 (San Diego Convention Center)
No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
Result Type: Paper
Number: 693
Presenter: Giorgia Battipaglia
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Finding the Ideal Donor and Graft: Going Beyond HLA
Time and Location:
Sunday, December 8, 2024: 4:30 PM-6:00 PM
Room 6A (San Diego Convention Center)
Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Result Type: Paper
Number: 749
Presenter: Yasmina Serroukh
Program: Oral and Poster Abstracts
Session: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Updates on Drug Treatments for Mantle Cell Lymphoma, and CAR-T and Transplants for Indolent Lymphomas
Time and Location:
Monday, December 9, 2024: 10:30 AM-12:00 PM
Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)
Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party
Result Type: Paper
Number: 851
Presenter: Ali Bazarbachi
Program: Oral and Poster Abstracts
Session: 618. Acute Myeloid Leukemias: Biomarkers and Molecular Marker in Diagnosis and Prognosis: Refining Diagnostic Risk Assessment
Time and Location:
Monday, December 9, 2024: 2:45 PM-4:15 PM
Grand Hall B (Manchester Grand Hyatt San Diego)
Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
Result Type: Paper
Number: 965
Presenter: Susana Rives
Program: Oral and Poster Abstracts
Session: 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Risk Stratification and CAR-T Therapies
Time and Location:
Monday, December 9, 2024: 4:30 PM-6:00 PM
Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)
Poster
Age Is a Crucial Determinant of GFRS with Incidence of Severe Chronic GVHD Reducing over Time in Haemopoietic Cell Transplantation for Transfusion Dependent Thalassaemia: Real World Data from 2010-2021. an Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
Result Type: Paper
Number: 2136
Presenter: Emanuele Angelucci
Program: Oral and Poster Abstracts
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I
Time and Location:
Saturday, December 7, 2024: 5:30 PM-7:30 PM
Halls G-H (San Diego Convention Center)
Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Result Type: Paper
Number: 2180
Presenter: Yishan Ye
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Time and Location:
Saturday, December 7, 2024: 5:30 PM-7:30 PM
Halls G-H (San Diego Convention Center)
Peripheral Blood Stem Cell Versus Bone Marrow Graft for Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT
Result Type: Paper
Number: 2190
Presenter: Arnon Nagler
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Time and Location:
Saturday, December 7, 2024: 5:30 PM-7:30 PM
Halls G-H (San Diego Convention Center)
Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT
Result Type: Paper
Number: 2333
Presenter: Valentin Ortiz-Maldonado
Program: Oral and Poster Abstracts
Session: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I
Time and Location:
Saturday, December 7, 2024: 5:30 PM-7:30 PM
Halls G-H (San Diego Convention Center)
Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party
Result Type: Paper
Number: 2185
Presenter: Nour Moukalled
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Time and Location:
Saturday, December 7, 2024: 5:30 PM-7:30 PM
Halls G-H (San Diego Convention Center)
Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party
Result Type: Paper
Number: 2184
Presenter: Josu de la Fuente
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Time and Location:
Saturday, December 7, 2024: 5:30 PM-7:30 PM
Halls G-H (San Diego Convention Center)
Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group
Result Type: Paper
Number: 1663
Presenter: Maria Carmen Martinez Munoz
Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I
Time and Location:
Saturday, December 7, 2024: 5:30 PM-7:30 PM
Halls G-H (San Diego Convention Center)
Comparative Safety and Efficacy of Posttransplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Cardiovascular Comorbidity Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission from Unrelated Donors: A Retrospective Pair-Match Analysis of EBMT ALWP
Result Type: Paper
Number: 2161
Presenter: Jan Vydra
Program: Oral and Poster Abstracts
Session: 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster I
Time and Location:
Saturday, December 7, 2024: 5:30 PM-7:30 PM
Halls G-H (San Diego Convention Center)
Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
Result Type: Paper
Number: 2193
Presenter: Jaime Sanz
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Time and Location:
Saturday, December 7, 2024: 5:30 PM-7:30 PM
Halls G-H (San Diego Convention Center)
Analysis of Outcomes after Second Allogeneic Stem Cell Transplant in Relapsed Acute Myeloid Leukaemia in Children: A Study from the EBMT Pediatric Diseases Working Party
Result Type: Paper
Number: 2182
Presenter: Nimrod Buchbinder
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Time and Location:
Saturday, December 7, 2024: 5:30 PM-7:30 PM
Halls G-H (San Diego Convention Center)
Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
Result Type: Paper
Number: 2379
Presenter: Andrew Cowan
Program: Oral and Poster Abstracts
Session: 907. Outcomes Research: Plasma Cell Disorders: Poster I
Time and Location:
Saturday, December 7, 2024: 5:30 PM-7:30 PM
Halls G-H (San Diego Convention Center)
Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT
Result Type: Paper
Number: 2188
Presenter: Arnon Nagler
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Time and Location:
Saturday, December 7, 2024: 5:30 PM-7:30 PM
Halls G-H (San Diego Convention Center)
Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT
Result Type: Paper
Number: 3570
Presenter: Jaime Sanz
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II
Time and Location:
Sunday, December 8, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Result Type: Paper
Number: 3027
Presenter: Yasmina Serroukh
Program: Oral and Poster Abstracts
Session: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
Time and Location:
Sunday, December 8, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Waldenström’s Macroglobulinemia. Report from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (LWP EBMT)
Result Type: Paper
Number: 3010
Presenter: Charalampia Kyriakou
Program: Oral and Poster Abstracts
Session: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
Time and Location:
Sunday, December 8, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)
Result Type: Paper
Number: 3497
Presenter: Martin Schmidt-Hieber
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster II
Time and Location:
Sunday, December 8, 2024, 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Result Type: Paper
Number: 3562
Presenter: Yishan Ye
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II
Time and Location:
Sunday, December 8, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
Result Type: Paper
Number: 3070
Presenter: Philipp Berning
Program: Oral and Poster Abstracts
Session: 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster II
Time and Location:
Sunday, December 8, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
Real-World Practice Patterns of Patient Management in the Peri-CAR T-Cell Therapy Setting for Patients with Mantle Cell Lymphoma: An International Survey on Behalf of the EBMT Lymphoma Working Party
Result Type: Paper
Number: 3656
Presenter: Gloria Iacoboni
Program: Oral and Poster Abstracts
Session: 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster II
Time and Location:
Sunday, December 8, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
Impact of Fludarabine Dosage on Outcomes in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy: A Retrospective Study on Behalf of the Ctiwp of the EBMT
Result Type: Paper
Number: 3456
Presenter: Guillaume Dachy
Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II
Time and Location:
Sunday, December 8, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
Total Body Irradiation Versus Chemotherapy Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia Patients Aged 2 to 4 Years: A Retrospective Study of the EBMT Pediatric Diseases Working Party
Result Type: Paper
Number: 3540
Presenter: Krzysztof Kalwak
Program: Oral and Poster Abstracts
Session: 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II
Time and Location:
Sunday, December 8, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
Result Type: Paper
Number: 4944
Presenter: Giorgia Battipaglia
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Time and Location:
Monday, December 9, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
Separation of Gvl Effects from GvHD with Ptcy-Based Gvhd Prophylaxis in Mmud Transplantation: A Study from the ALWP of the EBMT
Result Type: Paper
Number: 4895
Presenter: Frederic Baron
Program: Oral and Poster Abstracts
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III
Time and Location:
Monday, December 9, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
Outcome of Patients with HTLV-1 Adult T-Cell Leukemia/Lymphoma (ATL) after Allogeneic SCT: Results of the EBMT LWP
Result Type: Paper
Number: 4950
Presenter: Patricia Lopez Pereira
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Time and Location:
Monday, December 9, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP
Result Type: Paper
Number: 4315
Presenter: Iman Abou Dalle
Program: Oral and Poster Abstracts
Session: 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III
Time and Location:
Monday, December 9, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification – an EBMT ALWP Study
Result Type: Paper
Number: 4945
Presenter: Iman Abou Dalle
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Time and Location:
Monday, December 9, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party
Result Type: Paper
Number: 4942
Presenter: Ali Bazarbachi
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Time and Location:
Monday, December 9, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study
Result Type: Paper
Number: 4733
Presenter: Meral Beksac
Program: Oral and Poster Abstracts
Session: 654. Multiple Myeloma: Pharmacologic Therapies: Poster III
Time and Location:
Monday, December 9, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party
Result Type: Paper
Number: 4907
Presenter: Jurgen Kuball
Program: Oral and Poster Abstracts
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III
Time and Location:
Monday, December 9, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
Result Type: Paper
Number: 4939
Presenter: Antonio Jimenez Jimenez
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Time and Location:
Monday, December 9, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria – a Study on Behalf of Cmwp and Saawp of the EBMT
Result Type: Paper
Number: 4949
Presenter: Carmelo Gurnari
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Time and Location:
Monday, December 9, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT
Result Type: Paper
Number: 4894
Presenter: Yves Chalandon
Program: Oral and Poster Abstracts
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III
Time and Location:
Monday, December 9, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)